This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV1139

Psikotrop ilaç kullanan hastalarda potansiyel olarak anlamlı ilaç etkileşimlerinin değerlendirilmesi: gerçek yaşam verisine dayalı retrospektif çalışma (Assessment of potentially significant drug interactions in patients taking psychotropic medications: a retrospective study based on real-world data)

EVALUATION OF POTENTIALLY SIGNIFICANT DRUG-DRUG INTERACTIONS AMONG PATIENTS RECEIVING PSYCHOTROPIC MEDICATIONS: A REAL-WORLD RETROSPECTIVE STUDY

At least one potential drug interaction was identified in more than half of outpatients taking psychotropic medications, and the vast majority of these were moderate interactions (Category C) requiring therapy monitoring.

The aim of the study was to identify significant drug–drug interactions (DDIs) and report their prevalence among patients receiving psychotropic medications at the outpatient mental health clinics of the Enaya Continuing Care Compound (ECC2) in Qatar. The method involved a retrospective chart review of patients who obtained medications from the ECC2 pharmacy between March 1, 2022, and May 2022 and were taking at least one psychotropic medication; interactions were checked using Lexicomp Interact, and descriptive statistical analyses were performed using SPSS (IRB no. MRC-01-22-773). No interactions were identified in 49% of the 1,586 records reviewed, while at least one DDI was found in the remaining 807 patients (51%). These 807 patients had a mean age of 43.86 years (standard deviation 18.02), with 38–47 years being the most common age range (23.3%); approximately 44% had no comorbidities apart from their psychiatric condition, while 17% had at least one medical condition, and the most common diagnoses were depression (22.2%) and schizophrenia (21.9%). Patients were taking an average of 4.69±3.36 medications, of which 2.23±0.96 were psychotropic medications; the mean number of potential interactions per patient was 4.46±5.64, and the total number of potential interactions identified was 2,543. Most interactions were Category C, requiring therapy monitoring (86%, n=2,192), followed by Category D, requiring regimen modification (7.8%, n=200), and Category X, for which the combination should be avoided (1%, n=15). Category X interactions primarily involved the risk of QTc prolongation and torsades de pointes (quetiapine with sulpiride in 5 cases; combinations of flupentixol, quetiapine, and chlorpromazine; quetiapine with methadone), anticholinergic toxicity (fluphenazine or nortriptyline with ipratropium), reduced antipsychotic efficacy (olanzapine or paliperidone with cabergoline), and increased central nervous system depression (fluphenazine or paliperidone with orphenadrine). The authors state that the findings highlight pharmacists’ role in monitoring interactions, but that the retrospective design did not allow assessment of the clinical significance of the interactions or patient outcomes.

All WCP 2026 summaries